Search Result

Results for "

organ+damage

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (7) Angiotensin-converting Enzyme (ACE) (2) Apoptosis (3) Bacterial (3) Drug Metabolite (3) EGFR (2) Endogenous Metabolite (2) ERK (2) Melanocortin Receptor (2) Necroptosis (1) PSMA (1) Reference Standards (3) RIP kinase (1) Toll-like Receptor (TLR) (2)
By Research Areas:	Cancer (3) Cardiovascular Disease (3) Infection (5) Inflammation/Immunology (8) Metabolic Disease (5) Neurological Disease (8)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-13409

SB 242084 Maximum Cited Publications 6 Publications Verification	5-HT Receptor	Neurological Disease Metabolic Disease
SB 242084 is a selective, competitive and high-affinity (pK_i=9.0) 5-HT_2C receptor antagonist (crosses the blood-brain barrier). SB 242084 increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 also increases mitochondrial gene expression and oxidative metabolism via 5-HT_2A receptor. SB 242084 has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .

HY-118472

Benazeprilat CGS 14831	Drug Metabolite Endogenous Metabolite Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage .

HY-N2510

Myristicin Myristicine	5-HT Receptor EGFR ERK Apoptosis Bacterial	Infection Neurological Disease Inflammation/Immunology Cancer
Myristicine is an orally bioavailable serotonin receptor antagonist and weak monoamine oxidase (MAO) inhibitor. Myristicine also exerts anti-cancer effects on gastric cancer cells by inhibiting the EGFR/ERK signaling pathway. Myristicine is the main component of nutmeg essential oil and has anti-cancer, anti-proliferative, antibacterial, anti-inflammatory and apoptosis-inducing effects. Myristicine abuse can produce hallucinogenic effects, organ damage, etc .

HY-N8157

4'-O-Methylpyridoxine 1 Publications Verification	Others	Cardiovascular Disease Neurological Disease
4'-O-Methylpyridoxine is an orally active antivitamin B6 compound found in Ginkgo biloba seeds and leaves. 4'-O-Methylpyridoxine inhibits pyridoxal kinase. 4'-O-Methylpyridoxine reduces brain pyridoxal-5'-phosphate (PLP) levels, decreases gamma-aminobutyric acid/glutamate (GABA/Glu) ratio. 4'-O-Methylpyridoxine increases plasma levels of pyridoxal-5'-phosphate and pyridoxal. 4'-O-Methylpyridoxine induces hyperactivity, convulsions, pathological tissue changes, organ damage in rodent brain and heart .

HY-13409A

SB 242084 dihydrochloride Maximum Cited Publications 6 Publications Verification	5-HT Receptor	Neurological Disease Metabolic Disease
SB 242084 dihydrochloride is a selective, competitive and high-affinity (pK_i=9.0) 5-HT_2C receptor antagonist (crosses the blood-brain barrier). SB 242084 dihydrochloride increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 dihydrochloride also increases mitochondrial gene expression and oxidative metabolism via 5-HT_2A receptor. SB 242084 dihydrochloride has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .

HY-114256

EC1169	PSMA	Cancer
EC1169 is a cytotoxic maytansinoid conjugate that specifically binds to prostate-specific membrane antigen (PSMA). EC1169 precisely delivers the maytansinoid B hydrazide payload to PSMA-positive cells to exert antitumor activity. EC1169 only inhibits the growth of PSMA-positive cells but has no effect on PSMA-negative cells, and enables complete recovery in mice bearing PSMA-positive tumors. EC1169 exhibits safety with no body weight loss or major organ damage induced. EC1169 is used in studies of prostate cancer and other PSMA-expressing malignancies .

HY-P10208A

RKH acetate 1 Publications Verification	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
RKH acetate exerts protective effects against sepsis-induced death and organ damage. RKH acetate can directly bind to Toll-like receptor 4 (TLR4) and block TLR4 signal transduction in immune cells .

HY-P1208

PG-931	Melanocortin Receptor	Inflammation/Immunology
PG-931, an analog of SHU 9119 (HY-P0227), is a potent melanocortin 4 (MC4) receptor (IC₅₀=0.58 nM) agonist and is more selective than for the hMC3R (IC₅₀=55 nM) or the hMC5R (IC₅₀=2.4 nM). PG-931 can reverse haemorrhagic shock and prevent multiple organ damage in vivo .

HY-N7372

Licoisoflavanone	Apoptosis	Infection Inflammation/Immunology
Licoisoflavanone is an orally active isoflavane-based immunomodulator with multiple activities including antiviral, anti-inflammatory, cytoprotective and cancer cell apoptosis-inducing effects. Licoisoflavanone can be isolated from the roots and rhizomes of Glycyrrhiza uralensis Fisch. Licoisoflavanone not only enhances the body's immunity, but also effectively prevents acute respiratory distress syndrome and multiple organ damage by alleviating cytokine storm, thereby reducing the degree of inflammation. In rats, Licoisoflavanone undergoes multiple metabolic transformation processes such as glucuronidation, hydroxylation, sulfation, methylation and dehydrogenation. Licoisoflavanone has become an important candidate molecule for research on COVID-19 and related inflammatory diseases .

HY-N2510R

Myristicin (Standard) Myristicine (Standard)	5-HT Receptor EGFR ERK Reference Standards Apoptosis Bacterial	Infection Neurological Disease Inflammation/Immunology Cancer
Myristicin (Standard) is the analytical standard of Myristicin. This product is intended for research and analytical applications. Myristicine is an orally bioavailable serotonin receptor antagonist and weak monoamine oxidase (MAO) inhibitor. Myristicine also exerts anti-cancer effects on gastric cancer cells by inhibiting the EGFR/ERK signaling pathway. Myristicine is the main component of nutmeg essential oil and has anti-cancer, anti-proliferative, antibacterial, anti-inflammatory and apoptosis-inducing effects. Myristicine abuse can produce hallucinogenic effects, organ damage, etc .

HY-118472R

Benazeprilat (Standard) CGS 14831 (Standard)	Drug Metabolite Reference Standards Endogenous Metabolite Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Benazeprilat (Standard) is the analytical standard of Benazeprilat. This product is intended for research and analytical applications. Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage .

HY-P1208A

PG-931 TFA	Melanocortin Receptor	Inflammation/Immunology
PG-931 TFA, an analog of SHU 9119 (HY-P0227), is a potent melanocortin 4 (MC4) receptor (IC₅₀=0.58 nM) agonist and is more selective than for the hMC3R (IC₅₀=55 nM) or the hMC5R(IC₅₀=2.4 nM). PG-931 TFA can reverse haemorrhagic shock and prevent multiple organ damage in vivo .

HY-N3103R

p-Coumaric Acid Ethyl Ester (Standard) Ethyl (E)-p-hydroxycinnamate (Standard); Ethyl trans-4-hydroxycinnamate (Standard)	Reference Standards Drug Metabolite	Inflammation/Immunology
Benazeprilat (Standard) is the analytical standard of Benazeprilat. This product is intended for research and analytical applications. Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage .

HY-13409B

SB 242084 monohydrochloride	5-HT Receptor	Neurological Disease Metabolic Disease
SB 242084 monohydrochloride is a selective, competitive and high-affinity (pK_i=9.0) 5-HT_2C receptor antagonist (crosses the blood-brain barrier). SB 242084 monohydrochloride increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 also increases mitochondrial gene expression and oxidative metabolism via 5-HT_2A receptor. SB 242084 monohydrochloride has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .

HY-13409AR

SB 242084 dihydrochloride (Standard)	5-HT Receptor	Neurological Disease Metabolic Disease
SB 242084 (dihydrochloride) (Standard) is the analytical standard of SB 242084 (dihydrochloride). This product is intended for research and analytical applications. SB 242084 dihydrochloride is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 dihydrochloride increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 dihydrochloride also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 dihydrochloride has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .

HY-13409R

SB 242084 (Standard)	5-HT Receptor	Neurological Disease Metabolic Disease
SB 242084 (Standard) is the analytical standard of SB 242084. This product is intended for research and analytical applications. SB 242084 is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .

HY-183781

RIPK1-IN-41	RIP kinase Necroptosis	Inflammation/Immunology
RIPK1-IN-41 is an orally active RIPK1 inhibitor with an IC₅₀ of 92 nM and a K_D of 106.8 nM. RIPK1-IN-41 reduces the phosphorylation level of RIPK1, inhibits necrosome formation, blocks the activation of RIPK3 and MLKL, maintains mitochondrial and lysosomal functions, preserves cell membrane integrity, and suppresses necroptosis. RIPK1-IN-41 alleviates hypothermia and multi-organ damage in a mouse model of systemic inflammatory response syndrome induced by mTNF-α. RIPK1-IN-41 is applicable to research related to systemic inflammatory response syndrome .

HY-P11580

Pap12-6-10	Toll-like Receptor (TLR) Bacterial	Infection
Pap12-6-10 is an MD-2 ligand that binds to the hydrophobic pocket of MD-2 to inhibit the dimerization of the TLR4/MD-2 complex and downstream inflammatory signal transduction. Pap12-6-10 also binds to LPS to permeabilize bacterial cell membranes and induce oxidative stress, leading to bacterial death. Pap12-6-10 regulates LPS-induced inflammatory responses through the TLR4 signaling pathway and exhibits antibacterial activity against multidrug-resistant Gram-negative bacteria. Pap12-6-10 shows low tendency to induce drug resistance and low preclinical cytotoxicity, and it prevents organ damage in a mouse model of sepsis. Pap12-6-10 can be used for research related to Gram-negative sepsis and carbapenem-resistant Acinetobacter baumannii infections .

Cat. No.	상품명

HY-L145

Antihypertensive Compound Library	893 compounds
The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death. Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs). MCE offers a unique collection of 893 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

Antihypertensive Compound Library

893 compounds

The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death.

Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs).

MCE offers a unique collection of 893 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

Cat. No.	상품명	Target	Research Area